ArticleNature communications2023
Proteomic and genetic analyses of influenza A viruses identify pan-viral host targets.
Abstract read
In one paragraph
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Development of siRNA therapeutics to combat microbial infections: a bibliometric analysis.Frontiers in cellular and infection microbiology · 2025Pooled it
- Mapping in-cell protein contact sites reveals hijacking of paraspeckles during influenza A virus infection.Nature microbiology · 2026Article
- The cell with many faces: lung macrophage plasticity and function in response to environmental and pathogenic insults.Physiological reviews · 2026Review
- Degradation of ACSL3 by influenza A virus shifts unfolded protein response from antiviral defense to viral evasion.Virologica Sinica · 2026Article
- Divergent immunometabolic landscapes of chicken and swan goose identify SERPINF2 as a novel restriction factor for influenza A virus.Virology journal · 2026Article
- Article
- Article
- Investigating the Impact of Host Genetics on the Risk of Disease Progression in Individuals With Influenza.Immunity, inflammation and disease · 2026Article
- Enolase 1 suppresses influenza A virus replication by blocking the nuclear import of the viral ribonucleoprotein complex.Cellular and molecular life sciences : CMLS · 2026Article
- Multiomics Analysis of Arboviral Capsid Targets in Mosquitoes Reveals a Proviral Function of the Chromatin-Remodeling Brahma Complex.Molecular & cellular proteomics : MCP · 2026Article
- A novel targeted hybrid capture-NGS assay for sensitive detection of multiplex respiratory pathogens.Microbiology spectrum · 2026Article
- Comparative analysis of routine peripheral blood parameters in influenza and COVID-19 patients: a retrospective study.Revista do Instituto de Medicina Tropical de Sao Paulo · 2026Article
- Proteomic Analysis of Influenza.Advances in experimental medicine and biology · 2026Review
- From empirical vaccinology to predictive systems-based vaccine design: multi-omics integration, artificial intelligence, and global equity challenges.Frontiers in systems biology · 2026Review
- Integrating prior knowledge inference with computational multi-omics analysis to reveal host antiviral networks of natural compounds against influenza A virus.Frontiers in cellular and infection microbiology · 2026Article
- Article
- Systems Virology at Scale.Current opinion in systems biology · 2025Article
- Advancing influenza virus treatment:Materials today. Bio · 2025Article
- A metagenomic approach for microbial risk assessment and source attribution in high-risk ports of entry environments.Biosafety and health · 2025Article
- N-terminal acetylation controls multiple functional aspects of the influenza A virus ribonuclease PA-X.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
55 authors.
Kelsey M HaasJ. David Gladstone Institutes, San Francisco, CA, 94158, USA.ORCID http://orcid.org/0000-0002-1463-6726
Michael J McGregorJ. David Gladstone Institutes, San Francisco, CA, 94158, USA.
Mehdi BouhaddouJ. David Gladstone Institutes, San Francisco, CA, 94158, USA.
Benjamin J PolaccoDepartment of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, 94158, USA.ORCID http://orcid.org/0000-0003-1570-9234
Eun-Young KimDivision of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.ORCID http://orcid.org/0000-0002-7436-7396
Thong T NguyenJ. David Gladstone Institutes, San Francisco, CA, 94158, USA.
Billy W NewtonDepartment of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, 94158, USA.
Matthew UrbanowskiDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Heejin KimDivision of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.
Michael A P WilliamsQuantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG), San Francisco, CA, 94158, USA.
Veronica V RezeljQuantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG), San Francisco, CA, 94158, USA.
Alexandra HardyInstitut Pasteur, Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Paris, France.
Andrea FossatiJ. David Gladstone Institutes, San Francisco, CA, 94158, USA.
Erica J StevensonJ. David Gladstone Institutes, San Francisco, CA, 94158, USA.
Ellie SukermanDivision of Infectious Diseases, Oregon Health & Science University, Portland, OR, 97239, USA.
Tiffany KimDivision of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.ORCID http://orcid.org/0000-0001-8386-7686
Sudhir PenugondaDivision of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.
Elena MorenoDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.ORCID http://orcid.org/0000-0002-2301-4558
Hannes BrabergDepartment of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, 94158, USA.ORCID http://orcid.org/0000-0002-7070-2257
Yuan ZhouJ. David Gladstone Institutes, San Francisco, CA, 94158, USA.
Giorgi MetreveliDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Bhavya HarjaiJ. David Gladstone Institutes, San Francisco, CA, 94158, USA.
Tia A TumminoQuantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, 94158, USA.ORCID http://orcid.org/0000-0001-9155-820X
James E MelnykDepartment of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, 94158, USA.ORCID http://orcid.org/0000-0003-1915-8089
Margaret SoucherayJ. David Gladstone Institutes, San Francisco, CA, 94158, USA.ORCID http://orcid.org/0000-0002-0370-6653
Jyoti BatraJ. David Gladstone Institutes, San Francisco, CA, 94158, USA.
Lars PacheInfectious and Inflammatory Disease Center, Immunity and Pathogenesis Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.ORCID http://orcid.org/0000-0002-4193-1042
Laura Martin-SanchoDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Jared Carlson-StevermerSynthego Corporation, Redwood City, CA, 94063, USA.
Alexander S JurekaMolecular Virology and Vaccine Team, Immunology and Pathogenesis Branch, Influenza Division, National Center for Immunization & Respiratory Diseases, Centers for Disease Control & Prevention, Atlanta, GA, 30333, USA.
Christopher F BaslerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.ORCID http://orcid.org/0000-0003-4195-425X
Kevan M ShokatDepartment of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, 94158, USA.ORCID http://orcid.org/0000-0001-8590-7741
Brian K ShoichetQuantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, 94158, USA.ORCID http://orcid.org/0000-0002-6098-7367
Leah P ShriverDepartment of Chemistry, Washington University in St. Louis, St. Louis, MO, 63105, USA.
Jeffrey R JohnsonJ. David Gladstone Institutes, San Francisco, CA, 94158, USA.
Megan L ShawDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.ORCID http://orcid.org/0000-0002-1267-0891
Sumit K ChandaDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, 92037, USA.ORCID http://orcid.org/0000-0001-9399-7927
Dan M RodenDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Tonia C CarterCenter for Precision Medicine Research, Marshfield Clinic Research Institute, Marshfield, WI, 54449, USA.ORCID http://orcid.org/0000-0002-2107-7838
Leah C KottyanCenter of Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA.ORCID http://orcid.org/0000-0003-3979-2220
Rex L ChisholmCenter for Genetic Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.
Jennifer A PachecoCenter for Genetic Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.ORCID http://orcid.org/0000-0001-8021-5818
Maureen E SmithCenter for Genetic Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.ORCID http://orcid.org/0000-0001-9480-1092
Steven J SchrodiLaboratory of Genetics, School of Medicine and Public Health, University of Wisconsin Madison, Madison, WI, 53706, USA.ORCID http://orcid.org/0000-0003-2304-8528
Randy A AlbrechtDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.ORCID http://orcid.org/0000-0003-4008-503X
Marco VignuzziQuantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG), San Francisco, CA, 94158, USA.
Lorena Zuliani-AlvarezJ. David Gladstone Institutes, San Francisco, CA, 94158, USA.
Danielle L SwaneyJ. David Gladstone Institutes, San Francisco, CA, 94158, USA.ORCID http://orcid.org/0000-0001-6119-6084
Manon EckhardtJ. David Gladstone Institutes, San Francisco, CA, 94158, USA.ORCID http://orcid.org/0000-0001-8143-6129
Steven M WolinskyDivision of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.
Kris M WhiteQuantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG), San Francisco, CA, 94158, USA.ORCID http://orcid.org/0000-0003-0889-0506
Judd F HultquistQuantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG), San Francisco, CA, 94158, USA. judd.hultquist@northwestern.edu.ORCID http://orcid.org/0000-0001-6424-4280
Robyn M KaakeJ. David Gladstone Institutes, San Francisco, CA, 94158, USA. robyn.kaake@ucsf.edu.
Adolfo García-SastreQuantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG), San Francisco, CA, 94158, USA. adolfo.garcia-sastre@mssm.edu.ORCID http://orcid.org/0000-0002-6551-1827
Nevan J KroganJ. David Gladstone Institutes, San Francisco, CA, 94158, USA. nevan.krogan@ucsf.edu.ORCID http://orcid.org/0000-0003-4902-337X
Funding
MULTICENTER AIDS COHORT STUDYU01AI035039 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WOLINSKY, STEVEN M · 1993 to 2018
$66.4MNIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6MNorthwestern CORE Clinical Research Site: Trans-omics for HIV/AIDS ResearchU01HL146240 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Frank J Palella, Valentina Stosor · 2019 to 2026
$31.5MSARS-CoV adaptations through a Systems Biology Lens (SYBIL)U19AI135972 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Adolfo Garcia-Sastre · 2018 to 2026
$27.2MVirus CoreU19AI106754 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ALBRECHT, RANDY A. · 2013 to 2017
$26.0MTechnology Development Project - Increasing the complexity of ex vivo human airway models for studying immune response to viral infectionU19AI142733 · NIAID · JACKSON LABORATORY · PI Damien Chaussabel · 2019 to 2026
$23.1MRESEARCH PROJECT 2U19AI135990 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Melanie Maria Ott · 2018 to 2026
$21.4MVanderbilt Genome-Electronic Records (VGER) ProjectU01HG011181 · NHGRI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DAN M RODEN, Digna R Velez Edwards · 2020 to 2026
$7.0MVPS34 inhibitors as SARS-CoV-2 antiviralsR21AI161104 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BASLER, CHRISTOPHER F · 2021 to 2021
$429kSystematic Targeting of Oncogene Interacting Proteins to Reveal New Therapeutic StrategiesF32CA239333 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOUHADDOU, MEHDI · 2019 to 2021
$192kNCI NIH HHS F32 CA239333NHGRI NIH HHS U01 HG011181NHLBI NIH HHS U01 HL146240NIAID NIH HHS 75N93021C00014NIAID NIH HHS R21 AI161104NIAID NIH HHS U01 AI035039NIAID NIH HHS U19 AI106754NIAID NIH HHS U19 AI135972NIAID NIH HHS U19 AI135990NIAID NIH HHS U19 AI142733
Abstract
Influenza A Virus (IAV) is a recurring respiratory virus with limited availability of antiviral therapies. Understanding host proteins essential for IAV infection can identify targets for alternative host-directed therapies (HDTs). Using affinity purification-mass spectrometry and global phosphoproteomic and protein abundance analyses using three IAV strains (pH1N1, H3N2, H5N1) in three human cell types (A549, NHBE, THP-1), we map 332 IAV-human protein-protein interactions and identify 13 IAV-modulated kinases. Whole exome sequencing of patients who experienced severe influenza reveals several genes, including scaffold protein AHNAK, with predicted loss-of-function variants that are also identified in our proteomic analyses. Of our identified host factors, 54 significantly alter IAV infection upon siRNA knockdown, and two factors, AHNAK and coatomer subunit COPB1, are also essential for productive infection by SARS-CoV-2. Finally, 16 compounds targeting our identified host factors suppress IAV replication, with two targeting CDK2 and FLT3 showing pan-antiviral activity across influenza and coronavirus families. This study provides a comprehensive network model of IAV infection in human cells, identifying functional host targets for pan-viral HDT.
Indexed as
COVID-19Influenza A virusInfluenza A Virus, H5N1 SubtypeInfluenza, HumanAntiviral AgentsHost-Pathogen InteractionsHumansInfluenza A Virus, H3N2 SubtypeProteomicsSARS-CoV-2Virus ReplicationAntiviral Agents
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.